Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Powdermed To Conduct Clinical Trial Of Its Novel DNA-Based H5N1 (Avian) Influenza Vaccine In London

11.07.2006
PowderMed Ltd today announced that it has submitted regulatory documentation to the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for permission to conduct a clinical trial to test their proprietary H5N1 or avian influenza (bird flu) vaccine. It is planned that the trial will be conducted at a clinical research unit in London.

This new vaccine is based upon PowderMed’s proprietary system for delivering DNA vaccines – it is a needle-free injection device that fires gold particles coated with DNA (encoding genes specific to the flu strain) at supersonic speed into the immune cells of the skin. This first-time-in-man clinical trial will examine the ability of a vaccine based upon the Vietnam H5N1 avian influenza strain to protect against a potential pandemic form of flu.

A previous study, conducted by PowderMed in the United States, demonstrated that this vaccine technology was able to produce 100% protective immune responses in adult volunteers to a vaccine which encoded an annual influenza strain [Ref 1]. Using bird flu strains this vaccine has also shown 100% protection in various experimental models.

Dr Beadle, PowderMed’s Chief Medical Officer, stated that “This is an exciting opportunity for PowderMed to conduct the first clinical trial on a vaccine which may have a very important role in the event of a future pandemic. We have selected this particular clinical unit in London to conduct the study because they are currently building up a database of volunteers for future influenza studies. This will allow us to conduct the study and get the results as quickly as possible once we have regulatory approval.” Full details of this clinical study and directions for potential volunteers can be found at www.clinicaltrials.gov.

Dr Clive Dix, CEO of PowderMed also added: “Our approach provides a rapid route to vaccine development that can be applied to existing and emerging flu strains including, for example, the threat posed by a pandemic flu strain. DNA vaccines have a huge potential to limit the burden of disease and can be manufactured very rapidly, in large amounts: enough to vaccinate the whole of the UK population twice over (prime and boost) requires just 1Kg of DNA and can be manufactured and available in just three months from the point a strain is identified. We are very excited to see both our annual and pandemic influenza programmes progress through clinical development”.

Christelle Kerouedan | alfa
Further information:
http://www.powdermed.co.uk

More articles from Life Sciences:

nachricht 'Lipid asymmetry' plays key role in activating immune cells
20.02.2018 | Biophysical Society

nachricht New printing technique uses cells and molecules to recreate biological structures
20.02.2018 | Queen Mary University of London

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: In best circles: First integrated circuit from self-assembled polymer

For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.

In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

Im Focus: Hybrid optics bring color imaging using ultrathin metalenses into focus

For photographers and scientists, lenses are lifesavers. They reflect and refract light, making possible the imaging systems that drive discovery through the microscope and preserve history through cameras.

But today's glass-based lenses are bulky and resist miniaturization. Next-generation technologies, such as ultrathin cameras or tiny microscopes, require...

Im Focus: Stem cell divisions in the adult brain seen for the first time

Scientists from the University of Zurich have succeeded for the first time in tracking individual stem cells and their neuronal progeny over months within the intact adult brain. This study sheds light on how new neurons are produced throughout life.

The generation of new nerve cells was once thought to taper off at the end of embryonic development. However, recent research has shown that the adult brain...

Im Focus: Interference as a new method for cooling quantum devices

Theoretical physicists propose to use negative interference to control heat flow in quantum devices. Study published in Physical Review Letters

Quantum computer parts are sensitive and need to be cooled to very low temperatures. Their tiny size makes them particularly susceptible to a temperature...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

'Lipid asymmetry' plays key role in activating immune cells

20.02.2018 | Life Sciences

MRI technique differentiates benign breast lesions from malignancies

20.02.2018 | Medical Engineering

Major discovery in controlling quantum states of single atoms

20.02.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>